Identification of Molecular Factors Associated with Response to Interleukin-2

与 IL-2 反应相关的分子因素的鉴定

• 批准号: 8157715
• 负责人: James C Yang
• 金额: $ 25.94万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8157715
• 关键词: Interleukin-2; Molecular; response

To this point, over 70 patients (most with melanoma and including a dozen with objective clinical responses) have had serum and peripheral blood mononuclear cells (PBMC) collected during their initial therapy with IL-2. Over 30 immune related proteins have been interrogated in pretreatment sera by multiplex assay. The pre-treatment PBMC and the PBMC rebound occuring after stopping IL2 have been subjected to Affymetics array analysis which is still in process. Finding molecular factors associated with one of the only curative therapies for melanoma and renal cancer would not only allow treatment to focus on those most likely to benefit, but it could also provide clues to the mechanism by which IL-2 is working.

至此，超过70例患者（大多数患有黑色素瘤，包括十几个具有客观临床反应）的患者有血清和外周血单核细胞（PBMC）在初次使用IL-2治疗期间收集的。通过多重测定，已在预处理血清中询问了30多种免疫相关蛋白。停止IL2后发生的预处理PBMC和PBMC反弹已经进行了仍在处理的伴侣阵列分析。找到与黑色素瘤和肾癌唯一的治疗疗法之一相关的分子因素，不仅可以专注于最有可能受益的疗法，而且还可以为IL-2起作用的机制提供线索。